Cargando…
Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and top...
Autores principales: | Enokida, Hideki, Gotanda, Takenari, Oku, Shoichi, Imazono, Yoshiharu, Kubo, Hiroyuki, Hanada, Toshikatsu, Suzuki, Shigenori, Inomata, Kouhei, Kishiye, Takao, Tahara, Yoshiyuki, Nishiyama, Kenryu, Nakagawa, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927134/ https://www.ncbi.nlm.nih.gov/pubmed/12359058 http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x |
Ejemplares similares
-
Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report
por: Nishimura, Hiroaki, et al.
Publicado: (2018) -
Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020) -
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018) -
Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines
por: TATARANO, SHUICHI, et al.
Publicado: (2011) -
Metabolic engineering for the microbial production of isoprenoids: Carotenoids and isoprenoid-based biofuels
por: Niu, Fu-Xing, et al.
Publicado: (2017)